© 2026 CellCarta - All rights reserved.
Talk to the CellCarta Genomics Team
CellCarta’s genomics services offer precise biomarker data, without wasting time, tissue or budget. Our team helps biopharma programs choose the right assays for their needs, from focused PCR to targeted NGS panels, through to WES, RNASeq and WGS.
Get the data your program needs, while reducing workflow fragmentation, handoffs, and patient management friction.
One Partner. Endless Genomic Insights.
✔ Validated assays for patient management
✔ 470+ genomics projects delivered
✔ Genomics CRO services at the global scale
✔ Integrated tissue and liquid biopsy analysis
"Your RNASeq services are best in class and delivered lower duplication rates and much better unique read coverage…"
From Translational Research Through CDx Development — Genomic Lab Services That Scale with Your Program
CellCarta supports highly customized genomic biomarker testing and large-scale global studies across the full biomarker continuum — from translational research through clinical development and CDx commercialization. Start with the right assay depth and scale globally with CellCarta’s fully owned laboratory network.
Speak with a Scientist
Ready to start developing your assay?
Connect directly with our genomics CRO team. Tell us about your biomarker strategy, target indication, or study need - from focused PCR to broad genomic sequencing- and a CellCarta specialist will reach out to discuss the right assay approach.
➜ Fit-for-purpose genomic testing strategy aligned to your study decisions
➜ PCR services with validated workflows and rapid turnaround
➜ WES, RNASeq and WGS in one integrated operational model
➜ Global execution across North America, Europe, and China
Trusted by Our Clients
The CellCarta Genomics Expertise
Focused PCR
Use PCR workflows when known biomarkers need fast, actionable answers for patient management.
From single genes to the Biofidelity Aspyre® Lung assay, which provides NSCLC screening across 11 genes in tissue or blood with minimal input and a rapid turnaround.
The Lake Forest Expertise
Start focused when speed matters, expand to targeted NGS when you need insights into a range of actionable genomic alterations (AGAs), and go deeper into comprehensive DNA and RNA profiling when broader biology matters.
Clinical Trials Supported
470+
Focused PCR
Use PCR workflows when known biomarkers need fast, actionable answers for patient management. From single genes to the Biofidelity Aspyre® Lung assay, which provides NSCLC screening across 11 genes in tissue or blood with minimal input and a rapid turnaround.
470+
Clinical Trials Supported
Built Around the Right Decision, Not the Most Data.
Targeted NGS
NGS panels provide just the data you need, whether you're looking for specific mutations or wider panels of tumor biomarkers.
Whether 22 genes or panel of >500 genes is a better fit, targeted NGS is the answer when full sequencing would add unnecessary depth, cost, or complexity.
The Lake Forest Expertise
DNA and RNA sequencing
When the biology demands deeper insight, CellCarta provides WES, RNA-seq and WGS, without changing partners. These comprehensive sequencing options deliver high-quality in-depth data, for when you need a full picture.
The Lake Forest Expertise
Our Genomic Services Portfolio
Why teams choose CellCarta as their genomic services CRO: the right assays for the data you need, from targeted assays validated for patient management to full genomic sequencing
Validated HLA typing
For therapies that need human leukocyte antigen (HLA) typing for patient management, we determine HLA type (HLA-A, -B, -C, DRB1, DQB1 & DPB1) with greater accuracy than Sanger sequencing, in a NGS assay validated for clinical use.
The Lake Forest Expertise
From RUO to CTA
CellCarta elevates existing RUO and in-house assays (CTAs) into robust clinical trial assays for patient management. Plus, our in-house biobank can accelerate timelines with rapid access to more than 4,000 phenotype-characterized samples.
The Lake Forest Expertise
One Partner
Histopathology, tissue genomics, liquid biopsy, and HLA typing, all in one operational model. CellCarta's comprehensive laboratory services enable your patient management pipeline with fewer handoffs, for faster actionable answers.
The Lake Forest Expertise
Validated Assays
60+
Assay Development Projects
100+
CDx Projects Supported
30+
One CRO partner from specimen to smarter patient management decisions
CellCarta connects histopathology, IHC/IF, tissue genomics, liquid biopsy analysis, and HLA typing in one operational model.
When you need a partner to support therapeutic development and patient management, we offer comprehensive genomic laboratory services, with comprehensive multi-modal biomarker support. With validated assays and globally standardized execution across North America, Europe, and China, we're ready, wherever your trial takes you.
The result is fewer handoffs, better tissue optimization, and faster patient management decisions across the full biomarker continuum.
✔ Validated assays for patient management
✔ 470+ genomics projects delivered
✔ Genomics CRO services at the global scale
✔ Integrated tissue and liquid biopsy analysis
Start focused when speed matters, expand to targeted NGS when you need insights into a range of actionable genomic alterations (AGAs), and go deeper into comprehensive DNA and RNA profiling when broader biology matters.
Why teams choose CellCarta as their genomic services CRO: the right assays for the data you need, from targeted assays validated for patient management to full genomic sequencing
Built Around the Right Decision, Not the Most Data.
Our Genomics Service Portfolio
Targeted NGS
NGS panels provide just the data you need, whether you're looking for specific mutations or wider panels for tumor biomarkers.
Whether 22 genes or panel of >500 genes is a better fit, targeted NGS is the answer when full sequencing would add unnecessary depth, cost, or complexity.
DNA and RNA sequencing
When the biology demands deeper insight, CellCarta provides WES, RNA-seq and WGS, without changing partners. These comprehensive sequencing options deliver high-quality in-depth data, for when you need a full picture.
Validated HLA typing
For therapies that need human leukocyte antigen (HLA) typing for patient management, we determine HLA type (HLA-A, -B, -C, DRB1, -DQB1 & DPB1) with greater accuracy than Sanger sequencing, in a NGS assay validated for clinical use.
From RUO to CTA
CellCarta elevates existing RUO and in-house assays (CTAs) into robust clinical trial assays for patient management. Plus, our in-house biobank can accelerate timelines with rapid access to more than 4,000 phenotype-characterized samples.
One Partner.
Histopathology, tissue genomics, liquid biopsy, and HLA typing, all in one operational model. CellCarta's comprehensive laboratory services enable your patient management pipeline with fewer handoffs, for faster actionable answers.
Our Genomics Service Portfolio
One CRO partner from specimen to smarter patient management decisions
CellCarta connects histopathology, IHC/IF, tissue genomics, liquid biopsy analysis, and HLA typing in one operational model.
When you need a partner to support therapeutic development and patient management, we offer comprehensive genomic laboratory services, with comprehensive multi-modal biomarker support. With validated assays and globally standardized execution across North America, Europe, and China, we're ready, wherever your trial takes you.
The result is fewer handoffs, better tissue optimization, and faster patient management decisions across the full biomarker continuum.
60+
Validated Assays
100+
Assay Development Projects
470+
CDx Projects Supported